SanegeneBio Secures Nearly $100M in Series A+ Financing to Advance RNAi Therapeutics Development

December 1, 2023SANEGENEBIO Announces Over USD 80 Million (Nearly RMB 600 Million) in Series A+ Financing, Led by Tencent Investment and OrbiMed China, with Follow-on Investments from Northern Light Venture Capital, C&D Emerging Investment, Oriza Holdings, Shanghai Biomedical Industry Fund, Shenzhen Capital Group, and Teda Science & Technology Investment, alongside Existing Shareholders Qiming Venture Partners, Yahu Investment, and K2 Venture Partners.、TideFlow Capital、Lingang Lanwan Capital Continues to Support. The funds raised this time will be mainly used to accelerate the company's efforts in cardiovascular andMetabolic Diseases、IND applications and clinical trials for drug pipelines of immune-mediated diseases, as well as the advancement of extrahepatic delivery platform construction and drug development.

To date, SANEGENEBIO has secured over $130 million in cumulative funding across three rounds. In previous financing rounds, SANEGENEBIO received support from well-known investment firms such as K2VC, Hillhouse Ventures (GL Ventures), Qiming Venture Partners, TF Capital, YHC Investment, Lingang Blue Bay Capital, and Lanhu Capital.

Dr. Wang Weimin, founder and CEO of SANEGENEBIO, stated: "This round of financing is of great significance to the development of SANEGENEBIO. We are very grateful for the recognition and support from many investors. This financing will help us rapidly advance the clinical progress and internationalization of our core pipeline, strengthen the core competitiveness of our existing platform, develop new leading-edge technologies, address unmet clinical needs, and allow safe, effective, and accessible RNAi innovative therapies to benefit patients worldwide at an earlier stage."

A+ Round Lead Investor, YuanSheng Ventures, stated: "Small nucleic acid drugs are one of the most highly regarded innovative therapies in the biopharmaceutical field in recent years, with broad application prospects. Relying on the team's deep expertise in nucleic acid drug development technology and efficient execution, SANEGENEBIO has rapidly established a comprehensive RNAi drug research and development platform and built a rich product pipeline, accelerating the development of RNAi drugs with innovative and differentiated competitive advantages. YuanSheng Ventures is optimistic about SANEGENEBIO's growth potential in the RNAi field and hopes to help SANEGENEBIO’s new drug pipeline fully enter the clinical stage, bringing patients solutions with better efficacy and accessibility as soon as possible."

About SANEGENEBIO

SANEGENEBIO was founded in 2021 by a team of seasoned scientists in the field of nucleic acid drugs, dedicated to developing novel RNAi therapies. The company's core team has years of professional expertise and successful experience in large pharmaceutical companies and biotechnology firms. Shortly after its establishment, the company quickly built a proprietary nucleic acid drug chemical modification platform and intrahepatic and extrahepatic delivery technology platform. Based on the LEAD™ (Ligand and Enhancer Assisted Delivery) platform, SANEGENEBIO has laid out multiple drug pipelines, covering therapeutic areas such as cardiovascular and cerebrovascular diseases, metabolic disorders, immune-mediated diseases, and neurological conditions. Among these, the treatment for...HypercholesterolemiaSANEGENEBIO's Class 1 new drug SGB-3403 has entered the clinical trial stage in both China and Australia. One product has submitted an IND application in Australia, two products are in the IND-enabling stage, and other pipelines are also advancing simultaneously. SANEGENEBIO has also applied for comprehensive patent protection around the delivery platform, chemical modifications, target sequences, and candidate drug molecules, building a strong technical barrier.